KOBAYASHI PHARMACEUTICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30 EUR | -1.32% |
|
+1.35% | -28.91% |
| 06-24 | Kobayashi Pharmaceutical Co., Ltd.(TSE:4967) dropped from S&P Japan Mid Cap 100 | CI |
| 05-24 | Japan companies hog the spotlight as hedge funds tout their top Asia picks | RE |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company benefits from high valuations in earnings multiples.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Sector: Personal Products
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -28.91% | 2.46B | - | ||
| +12.74% | 390B | C- | ||
| +21.75% | 79.62B | A+ | ||
| -4.36% | 71.68B | A- | ||
| -27.28% | 38.13B | B+ | ||
| -14.96% | 35.06B | - | ||
| +0.41% | 33.01B | B- | ||
| +9.36% | 18.3B | A- | ||
| +21.45% | 16.83B | B | ||
| +8.84% | 12.87B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 4967 Stock
- KOY Stock
- Ratings Kobayashi Pharmaceutical Co., Ltd.
